Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Alys Hall who wrote (999)	1/5/1998 5:28:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 3702

Alys, Roger and Shero, it would be great to treat everyone possible but clinical trials are much too complex for the shotgun approach. Even though a Phase I is supposedly just for safety it involves much more than rhyme and reason. Check out this site virtualtrials.com and pay particular attention to Atlanta. Dosen't it make more sense to restrict the patients in P I to parameters that will allow the greatest consistency through P III, get the drug approved, and then treat everyone. TNT can do for solid tumors what Idec can only claim Rituxan can do for NHL. This is the first stateside TNT trial, let's do it right even if it means taking it slow. Our focus should be more on licensing deals than science anyway, at least most of us can understand the money side.